Zydus Cadila has received the tentative approval from the USFDA to market Lacosamide Tablets ( US RLD Vimpat) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg. Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain.
The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)